Source: Zealand Pharma A/S and reported by http://globenewswire.com/
Copenhagen, 2 June 2015 – Zealand Pharma A/S (“Zealand”) (NASDAQ Copenhagen: ZEAL) informs that new data will be presented on lixisenatide, the company’s first own-invented marketed medicine for the treatment of Type 2 diabetes, at the upcoming 75th Scientific Sessions of the American Diabetes Association (ADA) to be held in Boston on 5 – 9 June 2015. Further, at the event, Zealand will present two of its novel preclinical peptide therapeutics with potential for better treatment of diabetes and obesity.
Lixisenatide is marketed worldwide ex-US as Lyxumia® by Sanofi (SANF.PA) under a global license agreement. Lixisenatide is the first once-daily short-acting GLP-1 receptor agonist with a pronounced effect on prandial (meal-related) glucose and its therapeutic profile will be featured in a total of 13 presentations at ADA. These include important results of the cardiovascular safety outcome trial, ELIXA, to be unveiled in a symposium under the title:
“The Evaluation of Lixisenatide in Acute Coronary Syndrome —The Results of ELIXA”,
- See more at: http://globenewswire.com/news-release/2015/06/02/741240/0/en/New-data-on-lixisenatide-Lyxumia-including-ELIXA-results-on-LixiLan-and-on-novel-Zealand-peptide-therapeutics-to-be-presented-at-the-American-Diabetes-Association-s-ADA-75th-Scient.html#sthash.ncKCumSq.dpuf